Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
N Normanno, A Morabito, AM Rachiglio… - Nature Reviews …, 2025 - nature.com
Circulating tumour DNA (ctDNA) can be released by cancer cells into biological fluids
through apoptosis, necrosis or active release. In patients with non-small-cell lung cancer …
through apoptosis, necrosis or active release. In patients with non-small-cell lung cancer …
[HTML][HTML] Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives
P Hofman - Cancers, 2024 - mdpi.com
Simple Summary A liquid biopsy (LB) is now considered to be a valuable diagnostic tool for
advanced and metastatic nonsquamous nonsmall cell lung cancer (NS-NSCLC) patients …
advanced and metastatic nonsquamous nonsmall cell lung cancer (NS-NSCLC) patients …
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
G Guo, Z Zhang, J Zhang, D Wang, S Xu, G Liu… - Cancer Immunology …, 2024 - Springer
Objective Most recurrent glioblastoma (rGBM) patients do not benefit from immune
checkpoint inhibition, emphasizing the necessity for response biomarkers. This study …
checkpoint inhibition, emphasizing the necessity for response biomarkers. This study …
MBene Nanosheets with DNA Adsorbability for Circulating Tumor DNA Assay via Fluorescence Biosensing and Paper‐Based Microfluidic POCT
S Yang, J Zhu, L Zhao, L Yang, H Fa… - Advanced Functional …, 2024 - Wiley Online Library
The detection of circulating tumor DNA (ctDNA) in blood is significant for non‐invasive
cancer diagnosis and treatment monitoring. Herein, MBene nanosheets is synthesized and …
cancer diagnosis and treatment monitoring. Herein, MBene nanosheets is synthesized and …
[HTML][HTML] Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
The peri-operative management of non-small cell lung cancer (NSCLC) in earlier stage
disease has seen significant advances in recent years with the incorporation of immune …
disease has seen significant advances in recent years with the incorporation of immune …
The expanding role of circulating tumor DNA in resectable non–small cell lung cancer
D Morgensztern - Cancer, 2024 - Wiley Online Library
Despite treatment with curative intent, many patients with non–small cell lung cancer
develop tumor relapse. The detection of minimal residual disease with circulating tumor …
develop tumor relapse. The detection of minimal residual disease with circulating tumor …
The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer
G Passarella, S Canova, MI Abbate, G Caspani… - Discover Oncology, 2025 - Springer
Non-small cell lung cancer (NSCLC) remains a dire disease being the first cause of cancer
death among both genders. Early-stage NSCLC often has better treatment outcomes despite …
death among both genders. Early-stage NSCLC often has better treatment outcomes despite …
[HTML][HTML] The latest advances in liquid biopsy for lung cancer—a narrative review
W She, Y Garitaonaindia, Y Lin - Translational Lung Cancer …, 2024 - pmc.ncbi.nlm.nih.gov
Background and Objective Liquid biopsy has emerged as a transformative approach in the
diagnosis, monitoring, and treatment of lung cancer. This review aims to provide an updated …
diagnosis, monitoring, and treatment of lung cancer. This review aims to provide an updated …
Advancements in the clinical application of gene methylation for early cancer detection
X Xu, Y Guo, M Liu, Y Hu, S Li - Frontiers in Epigenetics and …, 2024 - frontiersin.org
This review provides an overview of common assays used to screen for gene methylation
and early biomarkers of methylation in various cancers. DNA methylation, one of the most …
and early biomarkers of methylation in various cancers. DNA methylation, one of the most …